Verde Servicos Internacionais S.A. Takes Position in Eli Lilly and Company $LLY

Key Points

• Verde Servicos Internacionais S.A. opened a new position in Eli Lilly during the first quarter, buying 2,000 shares worth about $1.84 million. The stake makes LLY its 27th-largest holding and represents about 0.6% of its portfolio.
• Institutional ownership remains very high, with 82.53% of Eli Lilly shares held by institutions. The article also notes several other funds recently added or increased positions in the company.
• Analysts remain broadly positive on Eli Lilly, with a consensus rating of “Moderate Buy” and an average price target of $1,230.89. Recent reports from firms including Goldman Sachs and Bank of America also showed continued bullish sentiment.

Verde Servicos Internacionais S.A. purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,000 shares of the company's stock, valued at approximately $1,840,000. Eli Lilly and Company accounts for approximately 0.6% of Verde Servicos Internacionais S.A.'s holdings, making the stock its 27th biggest position.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares during the period. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Finally, 10Elms LLP increased its holdings in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on LLY. Royal Bank Of Canada restated an "outperform" rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research note on Monday. Leerink Partners set a $1,119.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 26th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Bank of America increased their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a "buy" rating in a report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,230.89.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly completed its acquisition of Centessa Pharmaceuticals, strengthening its sleep-wake disorder pipeline and adding orexin-based drug development assets. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
• Positive Sentiment: The company announced a potential $1.9 billion research collaboration with Abbisko Therapeutics, expanding its global drug-discovery efforts and pipeline optionality. Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
• Positive Sentiment: Lilly said China approval for its GLP-1 obesity/diabetes pill could come as soon as later in 2026, reinforcing expectations for another major growth driver beyond Mounjaro and Zepbound. China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
• Positive Sentiment: Management also signaled a Europe launch strategy for the obesity pill, suggesting Lilly is preparing to expand its weight-loss franchise internationally as approvals progress. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY opened at $1,115.98 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.05 trillion, a PE ratio of 39.64, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53. The business's 50-day simple moving average is $1,026.17 and its 200-day simple moving average is $1,018.81.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business's revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's payout ratio is currently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.